TY - JOUR
T1 - Hope after salvage therapy fails
T2 - Novel agents for relapsed/refractory hodgkin lymphoma
AU - Kallam, Avyakta
AU - Vose, Julie M.
N1 - Funding Information:
research grant support from Acerta Pharma, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Incyte Corporation, Kite Pharma, Merck, Novartis, and Seattle Genetics. She also receives consulting/honoraria fees from AbbVie, Acerta/ Astra-Zeneca, BeiGene, Epizyme, Janssen/ Pharmacyclics, Karyopharm, Kite Pharma, Legend Biotech, Nordic Nanovector, Novartis, Roche, Sandoz, Vaniam Group, and Verastem Oncology. Dr. Kallam has no significant financial interest in the manufacturer of any product or provider of any service mentioned in this article.
Funding Information:
Dr. Vose receives research grant support from Acerta Pharma, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Incyte Corporation, Kite Pharma, Merck, Novartis, and Seattle Genetics. She also receives consulting/honoraria fees from AbbVie, Acerta/Astra-Zeneca, BeiGene, Epizyme, Janssen/Pharmacyclics, Karyopharm, Kite Pharma, Legend Biotech, Nordic Nanovector, Novartis, Roche, Sandoz, Vaniam Group, and Verastem Oncology. Dr. Kallam has no significant financial interest in the manufacturer of any product or provider of any service mentioned in this article.
Publisher Copyright:
© 2019 ONCOLOGY (United States). All rights reserved.
PY - 2019
Y1 - 2019
N2 - Hodgkin lymphoma is a highly curable malignancy, with an excellent prognosis. However, around 10% to 25% of patients will have primary refractory or relapsed disease, despite using riskadapted strategies. The standard of care for patients with relapsed/refractory Hodgkin lymphoma has been cytoreduction using salvage chemotherapy, followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT). Studies have shown that AHSCT produces a durable response rate of 50%, and that patients achieve a complete response with salvage chemotherapy. The outcomes for patients who do not respond to salvage chemotherapy or relapse after an AHSCT have been poor, with a median survival of 25 months. However, with the approval of novel agents over the last decade, the outcomes for patients with relapsed/refractory Hodgkin lymphoma have improved significantly. In this article, we present a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent.
AB - Hodgkin lymphoma is a highly curable malignancy, with an excellent prognosis. However, around 10% to 25% of patients will have primary refractory or relapsed disease, despite using riskadapted strategies. The standard of care for patients with relapsed/refractory Hodgkin lymphoma has been cytoreduction using salvage chemotherapy, followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT). Studies have shown that AHSCT produces a durable response rate of 50%, and that patients achieve a complete response with salvage chemotherapy. The outcomes for patients who do not respond to salvage chemotherapy or relapse after an AHSCT have been poor, with a median survival of 25 months. However, with the approval of novel agents over the last decade, the outcomes for patients with relapsed/refractory Hodgkin lymphoma have improved significantly. In this article, we present a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent.
UR - http://www.scopus.com/inward/record.url?scp=85069671150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069671150&partnerID=8YFLogxK
M3 - Review article
C2 - 31095720
AN - SCOPUS:85069671150
VL - 33
SP - 192
EP - 198
JO - Oncology
JF - Oncology
SN - 0890-9091
IS - 5
ER -